secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009878
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inogen prelim Q4 rev ~$82M (+2% YoY); FY25 rev ~$349M (+4%); order delays into H1 2026
--------------------------------------------------------------------------------

- Q4 2025 preliminary revenue ~$82M, up ~2% YoY; full-year 2025 ~$349M, up ~4% YoY.
- Company expects to achieve positive Adjusted EBITDA for full-year 2025.
- Shift in timing of a few large customer orders from Q4 2025 to H1 2026 caused disappointment.
- Full-year highlights: launches of Voxi 5 concentrator and Aurora Masks in U.S.; revenue growth and progress toward profitability.
- Full Q4/FY2025 results and 2026 guidance to be announced on February 24, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000119312526009878/0001193125-26-009878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000119312526009878/ingn-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer